Literature DB >> 22903396

[Indications for neoadjuvant or definitive radiochemotherapy in esophageal cancer of the highest evidence quality].

M Guckenberger1.   

Abstract

Entities:  

Year:  2012        PMID： 22903396     DOI： 10.1007/s00066-012-0213-1

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  5 in total

1.  Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis.

Authors:  Katrin M Sjoquist; Bryan H Burmeister; B Mark Smithers; John R Zalcberg; R John Simes; Andrew Barbour; Val Gebski
Journal:  Lancet Oncol       Date:  2011-06-16       Impact factor: 41.316

2.  Trading treatment toxicity for survival in locally advanced non-small cell lung cancer.

Authors:  M D Brundage; J R Davidson; W J Mackillop
Journal:  J Clin Oncol       Date:  1997-01       Impact factor: 44.544

3.  Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis.

Authors:  Val Gebski; Bryan Burmeister; B Mark Smithers; Kerwyn Foo; John Zalcberg; John Simes
Journal:  Lancet Oncol       Date:  2007-03       Impact factor: 41.316

4.  Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction.

Authors:  Michael Stahl; Martin K Walz; Martin Stuschke; Nils Lehmann; Hans-Joachim Meyer; Jorge Riera-Knorrenschild; Peter Langer; Rita Engenhart-Cabillic; Michael Bitzer; Alfred Königsrainer; Wilfried Budach; Hansjochen Wilke
Journal:  J Clin Oncol       Date:  2009-01-12       Impact factor: 44.544

5.  Fallacy of the five-year survival in lung cancer.

Authors:  B J McNeil; R Weichselbaum; S G Pauker
Journal:  N Engl J Med       Date:  1978-12-21       Impact factor: 91.245
  5 in total
  1 in total

1.  Adjuvant IMRT/XELOX radiochemotherapy improves long-term overall- and disease-free survival in advanced gastric cancer.

Authors:  J Boda-Heggemann; C Weiss; V Schneider; R-D Hofheinz; S Haneder; H Michaely; H Wertz; U Ronellenfitsch; A Hochhaus; F Wenz; F Lohr
Journal:  Strahlenther Onkol       Date:  2013-04-06       Impact factor: 3.621
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.